VF
HRTX icon

Virtu Financial’s Heron Therapeutics HRTX Stock Holding History

Virtu Financial’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-16,928
Closed -$21K – 1896
2025
Q3 		$21K Sell
16,928
-22,665
-57% -$35.9K ﹤0.01% 1271
2025
Q2 		$82K Buy
+39,593
New +$80.9K ﹤0.01% 1062
2024
Q3 		– Sell
-40,165
Closed -$141K – 1583
2024
Q2 		$141K Buy
+40,165
New +$123K 0.01% 782
2024
Q1 		– Sell
-41,237
Closed -$70K – 1694
2023
Q4 		$70K Buy
41,237
+25,608
+164% +$28.2K 0.01% 1112
2023
Q3 		$16K Buy
+15,629
New +$22.2K ﹤0.01% 1043
2022
Q3 		– Sell
-67,900
Closed -$189K – 1923
2022
Q2 		$189K Buy
67,900
+24,331
+56% +$97.7K 0.02% 772
2022
Q1 		$249K Buy
43,569
+25,263
+138% +$185K 0.02% 671
2021
Q4 		$167K Buy
+18,306
New +$187K 0.02% 905
2021
Q1 		– Sell
-20,667
Closed -$437K – 1787
2020
Q4 		$437K Buy
+20,667
New +$359K 0.05% 478
2020
Q3 		– Sell
-39,131
Closed -$576K – 1268
2020
Q2 		$576K Buy
+39,131
New +$643K 0.07% 332
2019
Q4 		$410K Buy
+17,460
New +$386K 0.04% 508
2018
Q4 		– Sell
-27,454
Closed -$869K – 1731
2018
Q3 		$869K Buy
27,454
+17,873
+187% +$666K 0.05% 382
2018
Q2 		$372K Buy
9,581
+7
+0.1% +$223 0.02% 996
2018
Q1 		$264K Sell
9,574
-43,515
-82% -$987K 0.01% 1149
2017
Q4 		$961K Buy
53,089
+21,495
+68% +$351K 0.05% 453
2017
Q3 		$510K Buy
+31,594
New +$496K 0.03% 918

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

Virtu Financial's HRTX Position: Q4 2025 in Review

Virtu Financial sold out of Heron Therapeutics (HRTX) in Q4 2025, closing a stake of 16,928 shares — an estimated $21K sold.

Virtu Financial first reported a position in HRTX in Q3 2017 and held it in 16 quarters. The position peaked at $961K in Q4 2017. 170 funds tracked by Wall St. Rank hold HRTX as of Q4 2025.

  • Virtu Financial reported no remaining Heron Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Virtu Financial sold 16,928 Heron Therapeutics shares in Q4 2025, an estimated $21K.
  • Virtu Financial first reported a position in Heron Therapeutics in Q3 2017 and held it in 16 quarters.
  • Virtu Financial's Heron Therapeutics position peaked at $961K in Q4 2017.
  • 170 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2025.

Based on Virtu Financial's 13F filing for Q4 2025, filed 23 Feb 2026.